Startups
EORTC (European Organisation for Research and Treatment of Cancer) is a non-profit organization that aims to improve the standard of cancer treatment in Europe by conducting clinical trials and research. Their website https://www.eortc.org/ provides information about their clinical trials database, quality of life questionnaire, and other resources.
Overview
Location
Belgium, Brussels, Woluwe-Saint-Lambert - Sint-Lambrechts-Woluwe
Employees
201-500
Founded date
1962
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 19, 2026 | CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress | CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress Thu, Mar 19, 2026 08:45 CET Report this content 19t... |
| Dec 11, 2025 | CHOSA - The market now doubles for Platin-DRP®, which predicts overall survival in lung cancer patients based on NanoString data | CHOSA - The market now doubles for Platin-DRP®, which predicts overall survival in lung cancer patients based on NanoString data Thu, Dec 11, 2025 14:12 CET Report this content The English text is an unofficial translation. In case of any d... |
| Sep 30, 2025 | CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer | CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer Tue, Sep 30, 2025 13:03 CET Report this content The English text is an unofficial translation. In case of any discr... |
| May 9, 2025 | CHOSA- Extending CHOSA’s Platin DRP: Predicting Carboplatin Efficacy in Breast Cancer | CHOSA- Extending CHOSA’s Platin DRP: Predicting Carboplatin Efficacy in Breast Cancer Fri, May 09, 2025 15:44 CET Report this content 09, May 2025 – CHOSA Today announced positive results from a retrospective study in a cohort of metastatic... |
| Mar 26, 2025 | CHOSA to Unveil Predictive Data for Cisplatin Response in Lung Cancer at end Q2 2025 – Advancing Precision Medicine for the World’s Most Widely Used Cancer Drug | CHOSA to Unveil Predictive Data for Cisplatin Response in Lung Cancer at end Q2 2025 – Advancing Precision Medicine for the World’s Most Widely Used Cancer Drug Wed, Mar 26, 2025 14:11 CET Report this content The English text is an unoffici... |
| Feb 10, 2025 | CHOSA announces a new collaboration with lung cancer experts paving the way for integration into clinical guidelines | CHOSA announces a new collaboration with lung cancer experts paving the way for integration into clinical guidelines Mon, Feb 10, 2025 08:40 CET Report this content This partnership leverages existing high-quality clinical data permitting e... |
| Apr 8, 2024 | OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board | OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board Mon, Apr 08, 2024 09:30 CET Report this content Stockholm, Sweden – April 8 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innov... |
| Apr 25, 2023 | HMP Global and EORTC announce partnership for the 25th annual World Congress on Gastrointestinal Cancer | HMP Global and EORTC announce partnership for the 25th annual World Congress on Gastrointestinal Cancer EORTC will coordinate symposium and workshop for young investigators; more than 3,000 delegates expected at the 28 June – 1 July event i... |
| Feb 22, 2023 | HMP Global and EORTC announce partnership for the 25th annual World Congress on Gastrointestinal Cancer | HMP Global and EORTC announce partnership for the 25th annual World Congress on Gastrointestinal Cancer EORTC will coordinate evening symposium and workshop for young investigators; over 3,000 delegates expected at 2023 event, held 28 June ... |
Show more
Reviews 0
FAQ about EORTC
When was EORTC founded?
EORTC was founded in 1962.
What has the press written about EORTC?
Parsers VC has collected 14 articles mentioning EORTC, among them “CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 202...” (Mar 19, 2026) and “CHOSA - The market now doubles for Platin-DRP®, which predicts overall survival in lung cancer patients based on NanoString data” (Dec 11, 2025).
Is EORTC still active?
Yes, EORTC is active; its latest activity on Parsers VC dates from Mar 26, 2026.